Fifth Third Wealth Advisors LLC Buys 2,190 Shares of Eli Lilly and Company $LLY

Key Points

• Fifth Third Wealth Advisors LLC increased its stake in Eli Lilly and Company by 14.4%, acquiring an additional 2,190 shares, bringing its total holdings to 17,395 shares valued at approximately $13.56 million.
• Insider transactions included Director J Erik Fyrwald purchasing 1,565 shares and CEO David A. Ricks acquiring 1,632 shares, reflecting confidence in the company's performance.
• Analysts have mixed views on Eli Lilly's stock, with Guggenheim raising its price target from $875 to $948, while others like Daiwa Capital Markets have downgraded their ratings.

Fifth Third Wealth Advisors LLC grew its stake in Eli Lilly and Company (NYSE:LLY - Free Report) by 14.4% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 17,395 shares of the company's stock after acquiring an additional 2,190 shares during the quarter. Fifth Third Wealth Advisors LLC's holdings in Eli Lilly and Company were worth $13,560,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the stock. Hobbs Wealth Management LLC raised its holdings in Eli Lilly and Company by 0.8% during the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock worth $1,205,000 after buying an additional 12 shares during the period. Hixon Zuercher LLC raised its holdings in Eli Lilly and Company by 0.7% during the 1st quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock worth $1,477,000 after buying an additional 12 shares during the period. O Brien Wealth Partners LLC raised its holdings in Eli Lilly and Company by 25.5% during the 1st quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock worth $49,000 after buying an additional 12 shares during the period. Ascent Capital Management LLC raised its holdings in Eli Lilly and Company by 2.5% during the 1st quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock worth $409,000 after buying an additional 12 shares during the period. Finally, Tennessee Valley Asset Management Partners raised its holdings in Eli Lilly and Company by 2.7% during the 1st quarter. Tennessee Valley Asset Management Partners now owns 493 shares of the company's stock worth $407,000 after buying an additional 13 shares during the period. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, Director J Erik Fyrwald acquired 1,565 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the completion of the acquisition, the director directly owned 74,578 shares in the company, valued at approximately $47,903,686.74. This trade represents a 2.14% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO David A. Ricks acquired 1,632 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was bought at an average price of $644.77 per share, for a total transaction of $1,052,264.64. Following the completion of the acquisition, the chief executive officer owned 546,601 shares of the company's stock, valued at approximately $352,431,926.77. The trade was a 0.30% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders purchased 4,514 shares of company stock valued at $2,894,841 in the last ninety days. 0.13% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several analysts have commented on the stock. Guggenheim raised their target price on shares of Eli Lilly and Company from $875.00 to $948.00 and gave the stock a "buy" rating in a report on Wednesday. Daiwa Capital Markets cut shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target for the company. in a research note on Sunday, August 17th. Wall Street Zen cut shares of Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research note on Saturday, September 20th. Leerink Partners reaffirmed a "market perform" rating and set a $715.00 price target on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Finally, Daiwa America cut shares of Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $948.56.

Eli Lilly and Company Price Performance

NYSE:LLY opened at $833.08 on Friday. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $937.00. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The firm has a fifty day simple moving average of $742.42 and a 200 day simple moving average of $765.94. The stock has a market capitalization of $788.47 billion, a PE ratio of 54.45, a P/E/G ratio of 1.16 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same period last year, the business earned $3.92 earnings per share. The firm's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, research analysts expect that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.